CN101585803A - 一种合成咔唑类化合物的方法 - Google Patents

一种合成咔唑类化合物的方法 Download PDF

Info

Publication number
CN101585803A
CN101585803A CNA200910099482XA CN200910099482A CN101585803A CN 101585803 A CN101585803 A CN 101585803A CN A200910099482X A CNA200910099482X A CN A200910099482XA CN 200910099482 A CN200910099482 A CN 200910099482A CN 101585803 A CN101585803 A CN 101585803A
Authority
CN
China
Prior art keywords
indoles
methyl
carbazole
cdcl
product
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
CNA200910099482XA
Other languages
English (en)
Other versions
CN101585803B (zh
Inventor
麻生明
孔望清
傅春玲
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Zhejiang University ZJU
Original Assignee
Zhejiang University ZJU
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Zhejiang University ZJU filed Critical Zhejiang University ZJU
Priority to CN200910099482XA priority Critical patent/CN101585803B/zh
Publication of CN101585803A publication Critical patent/CN101585803A/zh
Application granted granted Critical
Publication of CN101585803B publication Critical patent/CN101585803B/zh
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Landscapes

  • Indole Compounds (AREA)

Abstract

本发明涉及一种合成咔唑类化合物的方法,是在二氯化铂的催化下,1-(吲哚-2-基)-2,3-联烯醇高区域选择性地发生反应合成官能团化咔唑,本发明具有操作简单,原料和试剂易得,条件温和,反应具有高度的区域选择性等优点,并且能同时引入多个取代基,产物易分离纯化,适用于合成各种取代的咔唑类化合物。

Description

一种合成咔唑类化合物的方法
技术领域
本发明涉及一种高区域选择性地合成官能团化咔唑的方法,即1-(吲哚-2-基)-2,3-联烯醇在二氯化铂的催化下发生反应合成咔唑类化合物。
背景技术
咔唑作为精细化学品的重要的中间体,也是天然产物和药物中最常见的结构单元,具有多种重要的生理活性,在生物技术领域,医药及农药等方面有巨大的开发利用价值,同时被广泛应用于染料,颜料,塑料,橡胶,农药等诸领域。近年来国内外对咔唑及其衍生物的研究和应用正进一步深入,对咔唑的需求也激剧增加。但是简单,快捷,高效的合成咔唑及其衍生物的文献却很少报道(Angew.Chem.,Int.Ed.2002,41,3281;Org.Lett.2004,6,329;Org.Lett.2005,7,2543)。局限在于原料不易,反应条件苛刻,反应步骤多,而且产率不高。
发明内容
本发明目的就是提供一种简单,高效,快捷,高选择性的一步合成咔唑类化合物的方法。
本发明合成官能团化咔唑的方法,是在二氯化铂的催化下,1-(吲哚-2-基)-2,3-联烯醇高区域选择性地发生反应合成咔唑类化合物,反应式如下:
Figure A20091009948200031
R1=H、烷基或苯基,其中烷基为CnH2n+1,式中n=1-2;R2=H或甲基;R3=H、烷基、烯丙基、苯基、酯基COOEt、酰胺基CON(CH3)2或醇羟基CH2OH,其中烷基为CnH2n+1,式中n=1-4;R4=H、烷基或苄基,其中烷基为CnH2n+1,式中n=1-6;R5=H或甲基,R6=H、甲基或甲氧基,R7=H或甲基,其步骤是:
(1)依次将1-(吲哚-2-基)-2,3-联烯醇、二氯化铂加入到甲苯中,然后在室温下搅拌反应2-19小时;
(2)浓缩,快速柱层析,得咔唑衍生物。
本发明的有机溶剂为甲苯。1-(吲哚-2-基)-2,3-联烯醇与二氯化铂的摩尔比为:1∶0.05-0.055,最好为1∶0.05。
本发明的1-(吲哚-2-基)-2,3-联烯醇与甲苯的摩尔比为:0.18-0.2mmol/1mL,最好为0.2mmol/1mL。
本发明涉及一种1-(吲哚-2-基)-2,3-联烯醇在二氯化铂的催化下发生反应,高区域选择性地合成咔唑类化合物的方法。本方法操作简单,原料和试剂易得,反应具有高度的区域选择性,反应条件温和,适用于合成各种取代的咔唑。
本发明克服了传统方法的弊端,具有以下优点:1)反应具有高度的区域选择性;2)易操作,产率较高;3)产物易分离纯化;4)反应条件温和;5)环境友好。
本发明创新点在于发展了一种高区域选择性地合成咔唑类化合物的方法学。
本发明所得的相应的咔唑类化合物的产率为50-86%。
具体实施方式
实施例1
室温下加入二氯化铂(2.9mg,0.011mmol),1-(1-乙基-吲哚-2-基)-2,3-壬二烯-1-醇(57.0mg,0.20mmol)和甲苯(1mL),然后在室温下2小时反应完全,浓缩,快速柱层析,得产物9-乙基-4-戊基-咔唑44.4mg,产率为83%。产物为无色液体。
1H NMR(300MHz,CDCl3)δ8.13(d J=7.8Hz,1H),7.52-7.34(m,3H),7.32-7.20(m,2H),7.02(d,J=7.2Hz,1H),4.36(q,J=7.2Hz,2H),3.22(t,J=7.8Hz,2H),1.92-1.78(m,2H),1.58-1.33(m,7H),0.93(t,J=7.2Hz,3H);13CNMR(75MHz,CDCl3)δ140.2,139.8,138.6,125.4,124.9,122.9,122.7,120.7,119.5,118.7,108.2,106.0,37.4,345,32.1,29.4,22.7,14.1,13.7;IR(neat),v(cm-1)3049,2955,2930,2860,1618,1594,1581,1498,1469,1435,1381,1329,1297,1245,1216,1151,1110,1079,1027;MS(70ev,EI)m/z(%)266(M++1,21.45),265(M+,100);HRMS Calcd for C19H23N(M+):265.1830, Found:265.1829.
实施例2
按实施例1所述的方法,不同的是所用底物和试剂为:二氯化铂(5.3mg,0.02mmol),1-(1-乙基-吲哚-2-基)-2,3-戊二烯-1-醇(90.9mg,0.40mmol)和甲苯(2mL),然后在室温下2小时反应完全,浓缩,快速柱层析,得产物4-甲基-9-乙基-咔唑71.9mg,产率为86%。产物为无色液体。
1HNMR(300MHz,CDCl3)δ8.20(d,J=7.8Hz,1H),7.51-7.32(m,3H),7.30-7.18(m,2H),7.00(d,J=6.9Hz,1H),4.35(q,J=7.2Hz,2H),2.89(s,3H),1.40(t,J=7.2Hz,3H);13C NMR(75MHz,CDCl3)δ139.9,139.8,133.5,125.4,124.9,123.5,122.7,121.4,120.3,118.7,108.1,106.0,37.4,20.8,13.7;IR(neat),v(cm-1)3049,2974,2933,1618,1594,1576,1498,1470,1454,1427,1385,1327,1292,1250,1221,1150,1107,1081,1026,1012;MS(70ev,EI)m/z(%)210(M++1,9.17),209(M+,53.14),194(M+-CH3,100);HRMS Calcd forC15H15N(M+):209.1204,Found:209.1205.
实施例3
按实施例1所述的方法,不同的是所用底物和试剂为:二氯化铂(4.2mg,0.016mmol),1-(1-乙基-吲哚-2-基)-2-甲基-2,3-癸二烯-1-醇(90.2mg,0.29mmol)和甲苯(1.5mL),然后在室温下2小时反应完全,浓缩,快速柱层析,得产物1-甲基-4-己基-9-乙基-咔唑68.8mg,产率为81%。产物为无色液体。
1HNMR (300MHz,CDCl3)δ8.12(d,J=8.1Hz,1H),7.51-7.40(m,2H),7.29-7.20(m,1H),7.11(d,J=7.2Hz,1H),6.91(d,J=7.5Hz,1H),4.62(q,J=7.2Hz,2H),3.19(t,J=7.8Hz,2H),2.81(s,3H),1.90-1.75(m,2H),160-1.47(m,2H),1.43(d,J=7.2Hz,3H),1.37-1.28(m,4H),0.95-0.85(m,3H);13C NMR(75MHz,CDCl3)δ140.5,138.9,136.3,128.7,124.8,123.1,122.6,121.4,119.7,118.8,117.2,108.4,39.2,34.3,31.8,29.61,29.59,22.7,20.1,15.5,14.1;IR(neat),v(cm-1)3048,3013,2955,2928,2857,1611,1577,1512,1463,1394,1378,1350,1323,1252,1230,1161,1148,1118,1082,1029;MS(70ev,EI)m/z(%)294(M++1,36.81),293(M+,100);HRMS Calcdfor C21H27N(M+):293.2144,Found:293.2135.
实施例4
按实施例1所述的方法,不同的是所用底物和试剂为:二氯化铂(4.0mg,0.015mmol),1-(1-乙基-5-甲基-吲哚-2-基)-2,3-癸二烯-1-醇(92.0mg,0.30mmol)和甲苯(1.5mL),然后在室温下2小时反应完全,浓缩,快速柱层析,得产物3-甲基-5-己基-9-乙基-咔唑65.1mg,产率为75%。产物为无色液体。
1HNMR (300MHz,CDCl3)δ7.92(s,1H),7.41-7.17(m,4H),6.98(d,J=7.2Hz,1H),4.31(q,J=7.2Hz,2H),3.21(t,J=78Hz,2H),2.56(s,3H),1.93-1.76(m,2H),1.62-1.45(m,2H),1.44-1.27(m,7H),0.91(t,J=6.9Hz,3H);13C NMR (75MHz,CDCl3)δ140.5,138.6,138.1,127.8,126.1,125.2,123.0,122.8,120.5,119.2,107.8,105.9,37.4,34.5,31.8,29.7,29.5,22.7,21.6,14.1,13.7;IR(neat),v(cm-1)2955,2928,2858,1615,1597,1579,1499,1476,1379,1331,1309,1248,1150,1116,1080;MS(70ev,EI)m/z(%)294(M++1,22.27),293(M+,100);HRMS Calcd for C21H27N(M+):293.2144,Found:293.2131.
实施例5
按实施例1所述的方法,不同的是所用底物和试剂为:二氯化铂(4.1mg,0.015mmol),1-(1-乙基-5-甲氧基-吲哚-2-基)-2,3-癸二烯-1-醇(92.5mg,0.28mmol)和甲苯(1.5mL),然后在室温下3小时反应完全,浓缩,快速柱层析,得产物3-甲氧基-5-己基-9-乙基-咔唑65.3mg,产率为75%。产物为无色液体。
1HNMR(300MHz,CDCl3)δ7.65(d,J=2.1Hz,1H),7.40-7.28(m,2H),7.26-7.18(m,1H),7.11(dd,J=8.7and 2.4Hz,1H),6.97(d,J=7.2Hz,1H),4.30(q,J=7.2Hz,2H),3.93(s,3H),3.19(t,J=7.8Hz,2H),1.92-1.78(m,2H),1.61-1.46(m,2H),1.45-1.27(m,7H),0.90(t,J=6.9Hz,3H);13C NMR(75MHz,CDCl3)δ153.3,140.8,138.5,134.9,125.4,123.1,120.5,119.0,113.4,108.6,106.4,106.1,56.1,37.4,34.5,31.9,29.9,29.7,22.7,14.1,13.7;IR(neat),v(cm-1)3047,2930,2858,1624,1598,1580,1498,1479,1437,1378,1305,1287,1224,1206,1150,1102,1039;MS(70ev,EI)m/z(%)310(M++1,23.35),309(M+,100);HRMS Calcd forC21H27NO(M+):309.2093,Found:309.2101.
实施例6
按实施例1所述的方法,不同的是所用底物和试剂为:二氯化铂(2.8mg,0.011mmol),1-(1-乙基-吲哚-2-基)-5-苯基-2,3-戊二烯-1-醇(60.2mg,0.20mmol)和甲苯(1mL),然后在室温下5小时反应完全,浓缩,快速柱层析,得产物4-苄基-9-乙基-咔唑28.7mg,产率为50%。产物为无色液体。
1HNMR(300MHz,CDCl3)δ8.07(d,J=8.1Hz,1H),7.48-7.12(m,10H),6.91(d,J=7.5Hz,1H),4.65(s,2H),4.37(q,J=7.2Hz,2H),1.43(t,J=7.2Hz,3H);13C NMR(75MHz,CDCl3)δ140.2.139.9,135.7,128.9,128.5,126.0,125.5,125.1,122.85,122.79,121.3,120.5,118.7,108.2,106.6,39.9,37.5,13.7;IR(neat),v(cm-1)3039,2974,2919,1618,1594,1495,1460,1435,1383,1330,1244,1153,1104,1029;MS(70ev,EI)m/z(%)286(M++1,19.99),285(M+,90.76),270(M+-CH3,100);HRMS Calcd for C21H19N(M+):285.1517,Found:285.1517.
实施例7
按实施例1所述的方法,不同的是所用底物和试剂为:二氯化铂(5.4mg,0.02mmol),1-(1-乙基-吲哚-2-基)-2-苯基-2,3-丁二烯-1-醇(116.0mg,0.4mmol)和甲苯(2mL),然后在室温下4小时反应完全,浓缩,快速柱层析,得产物2-苯基-9-乙基-咔唑76.2mg,产率为70%。产物为浅黄色固体。
m.p.118-119℃(CH2Cl2/n-heaxane),1HNMR(300MHz,CDCl3)δ8.18-8.08(m,2H),7.78-7.70(m,2H),7.58(d,J=1.2Hz,1H),7.54-7.32(m,6H),7.28-7.20(m,1H),4.40(q,J=7.2Hz,2H),1.45(q,J=7.2Hz,3H);13CNMR(75MHz,CDCl3)δ142.2,140.4,139.1,128.8,127.6,127.0,125.6,122.7,122.1,120.6,120.4,118.9,118.5,108.4,107.0,37.5,13.8;IR(neat),v(cm-1)3057,2975,2931,1627,1599,1564,1488,1470,1457,1436,1380,1328,1255,1232,1156,1125,1087;MS(70ev,EI)m/z(%)272(M++1,18.05),271(M+,80.40),256(M+-CH3,100);HRMS Calcd for C20H17N(M+):271.1361,Found:271.1360.
实施例8
按实施例1所述的方法,不同的是所用底物和试剂为:二氯化铂(5.4mg,0.02mmol),1-(1-乙基-吲哚-2-基)-2-丁基-2,3-丁二烯-1-醇(100.1mg,0.37mmol)和甲苯(2mL),然后在室温下3小时反应完全,浓缩,快速柱层析,得产物2-丁基-9-乙基-咔唑69.1mg,产率为74%。产物为无色液体。
1HNMR(300MHz,CDCl3)δ8.06(dt,J=7.8and 0.9Hz,1H),8.00(d,J=7.8Hz,1H),7.48-7.36(m,2H),7.25-7.17(m,2H),7.07(dd,J=7.8and 1.2Hz,1H),4.36(q,J=7.2Hz,2H),2.83(t,J=7.8Hz,2H),1.79-1.66(m,2H),1.49-1.38(m,5H),0.97(t,J=7.4Hz,3H);13C NMR(75MHz,CDCl3)δ141.0,140.3,140.0,125.0,123.0,120.8,120.0,119.7,118.6,108.2,107.9,37.4,36.5,34.3,22.5,14.0,13.8;IR(neat),v(cm-1)3051,2955,2929,2857,1685,1629,1602,1577,1498,1458,1377,1326,1234,1180,1155,1133,1120,1102,1086,1058,1020,1000;MS(70ev,EI)m/z(%)251(M+,36.24),194(M+-C4H9,100);HRMS Calcd for C18H21N(M+):251.1674,Found:251.1672.
实施例9
按实施例1所述的方法,不同的是所用底物和试剂为:二氯化铂(5.2mg,0.02mmol),1-(1-甲基-吲哚-2-基)-2-苯基-2,3-丁二烯-1-醇(110.1mg,0.40mmol)和甲苯(2mL),然后在室温下4小时反应完全,浓缩,快速柱层析,得产物2-苯基-9-甲基-咔唑83.5mg,产率为81%。产物为无色液体。
1HNMR(300MHz,CDCl3)δ8.12(t,J=8.4Hz,2H),7.73(d,J=7.2Hz,2H),7.58(s,1H),7.56-7.44(m,4H),7.43-7.31(m,2H),7.30-7.19(m,1H),3.88(s,3H);13C NMR(75MHz,CDCl3)δ142.2,141.44,141.42,139.1,128.7,127.5,127.0, 125.6,122.5,122.0,120.5,1203,119.0,118.5,108.4,107.0,29.0;IR(KBr),v(cm-1)3050,2927,1626,1599,1561,1491,1465,1454,1439,1421,1360,1341,1324,1248,1225,1160,1124,1076,1060,1017;MS(70ev,EI)m/z(%)258(M++1,20.65),257(M+,100);HRMS Calcd for C19H15N(M+):257.1204,Found:257.1203.
实施例10
按实施例1所述的方法,不同的是所用底物和试剂为:二氯化铂(5.2mg,0.02mmol),1-(1-甲基-吲哚-2-基)-2-丁基-2,3-丁二烯-1-醇(102.1mg,0.40mmol)和甲苯(2mL),然后在室温下4小时反应完全,浓缩,快速柱层析,得产物2-丁基-9-甲基-咔唑67.2mg,产率为71%。产物为无色液体。
1HNMR(300MHz,CDCl3)δ8.03(dt,J=7.8and0.9Hz,1H),7.97(d,J=78Hz,1H),7.48-7.38(m,1H),7.37-7.30(m,1H),7.24-7.15(m,2H),7.05(dd,J=7.8and1.5Hz,1H),3.78(s,3H),2.81(t,J=7.8Hz,2H),178-1.63(m,2H),1.48-1.33(m,2H),0.96(t,J=7.2Hz,3H);13C NMR(75MHz,CDCl3)δ141.3,141.0,125.0,122.8,120.6,119.9,119.7,118.6,108.2,107.9,36.5,34.3,28.9,22.5,14.0;IR(neat),v(cm-1)3054,3025,2955,2928,2857,1631,1603,1564,1468,1455,1420,1377,1360,1337,1322,1248,1156,1132,1118,1000;MS(70ev,EI)m/z(%)238(M++1,28.31),237(M+,3488),194(M+-C4H9,100);HRMS Calcd for C17H19N(M+):237.1517,Found:237.1516.
实施例11
按实施例1所述的方法,不同的是所用底物和试剂为:二氯化铂(5.3mg,0.02mmol),1-(1-乙基-吲哚-2-基)-2-烯丙基-2,3-丁二烯-1-醇(100.2mg,0.39mmol)和甲苯(2mL),然后在室温下3小时反应完全,浓缩,快速柱层析,得产物2-烯丙基-9-乙基-咔唑69.2mg,产率为74%。产物为无色液体。
1HNMR(300MHz,CDCl3)δ8.30-8.15(m,2H),7.67-7.55(m,1H),7.51(d,J=8.1Hz,1H),7.45-7.35(m,2H),7.30-7.21(m,1H),6.39-7.21(m,1H),5.43-5.25(m,2H),4.43(q,J=7.2Hz,2H),3.79(d,J=6.3Hz,2H),1.54(t,J=7.2Hz,3H);13C NMR(75MHz,CDCl3)δ140.2.139.9,137.9,137.8,125.1,122.8,121.1,120.2,120.1,119.7,118.6,115.6,108.3,108.1,40.9,37.2,13.7;IR (neat),v(cm-1)3057,2975,2932,2895,1629,1601,1572,1496,1479,1469,1460,1378,1336,1327,1236,1177,1156,1132,1119,1086,1058,1020,1000;MS(70ev,EI)m/z(%)236(M++1,14.21),235(M+,9955),234(M+-H,100);HRMS Calcd for C17H17N(M-):235.1361,Found:235.1360.
实施例12
按实施例1所述的方法,不同的是所用底物和试剂为:二氯化铂(4.2mg,0.016mmol),1-(1-乙基-5-甲基-吲哚-2-基)-2-苯基-2,3-丁二烯-1-醇(91.5mg,0.30mmol)和甲苯(1.5mL),然后在室温下17小时反应完全,浓缩,快速柱层析,得产物2-苯基-6-甲基-9-乙基-咔唑60.2mg,产率为70%。产物为浅黄色固体。
m.p.107-108℃(CH2Cl2/n-heaxane).1HNMR(300MHz,CDCl3)δ8.13(d,J=7.8Hz,1H),7.93(s,1H),7.80-7.70(m,2H),7.58(d,J=1.2Hz,1H),7.55-7.44(m,3H),7.43-7.28(m,3H),4.41(q,J=7.Hz,2H),2.57(s,3H),1.46(t,J=7.2Hz,3H);13C NMR(75MHz,CDCl3)δ142.3,140.6,138.9,138.7,128.7,128.2,127.6,127.0,126.9,122.8,122.0,120.5,120.4,118.2,108.1,106.9,37.5,21.4,13.8;IR(neat),v(cm-1)3027,2974,2918,1600,1563,1486,1469,1439,1367,1339,1298,1236,1224,1149,1088;MS(70ev,EI)m/z(%)286(M++1,19.40),285(M+,84.33),270(M+-CH3,100);HRMS Calcd for C21H19N(M+):285.1517,Found:285.1527.
实施例13
按实施例1所述的方法,不同的是所用底物和试剂为:二氯化铂(4.1mg,0.015mmol),1-(1-苯基-吲哚-2-基)-2-苯基-2,3-丁二烯-1-醇(100.0mg,0.30mmol)和甲苯(1.5mL),然后在室温下19小时反应完全,浓缩,快速柱层析,得产物2-苯基-9-苯基-咔唑74.3mg,产率为78%。产物为浅黄色固体。
m.p.118-119℃(CH2Cl2/n-heaxane).1HNMR(300MHz,CDCl3)δ8.28-8.13(m,2H),7.75-7.7.41(m,13H),7.40-7.28(m,2H);13C NMR(75MHz,CDCl3)δ141.9,141.39,141.38,139.4,137.6,129.9,128.7,127.5,127.2,127.0,125.9,123.1,122.5,120.5,120.3,120.0,119.6,109.8,108.2;IR(neat),v(cm-1)3059,1626,1598,1558,1501,1484,1457, 1428,1364,1339,1319,1236,1218,1127,1073;MS(70ev,EI)m/z(%)320(M++1,25.63),319(M+,100);HRMS Calcd for C24H17N(M+):319.1361,Found:319.1374.
实施例14
按实施例1所述的方法,不同的是所用底物和试剂为:二氯化铂(4.1mg,0.015mmol),2-((1-乙基-吲哚-2-基)-羟甲基)-2,3-丁二烯酸甲酯(83.0mg,0.30mmol)和甲苯(1.5mL),然后在室温下36小时反应完全,浓缩,快速柱层析,得产物(9-乙基-咔唑-2-基)甲酸甲酯51.8mg,产率为67%。产物为无色液体。
1HNMR(300MHz,CDCl3)δ8.15-8.02(m,3H),7.89(dd J=8.1 and 1.2Hz,1H),7.55-7.44(m,1H),7.38(d,J=8.4Hz,1H),7.26-7.17(m,1H),4.36(q,J=7.2Hz,2H),3.95(s,3H),1.40(t,J=7.2Hz,3H);13CNMR(75MHz,CDCl3)δ167.9,141.1,139.2,126.94,126.86,126.5,122.0,121.1,119.93,119.90,119.2,110.2,108.8,52.1,37.6,13.9;IR(neat)v cm-1)3057,2976,2950,1715,1628,1600,1572,1480,1443,1380,1341,1328,1303,1284,1254,1231,1218,1157,1131,1098,1057;MS(70ev,EI)m/z(%)254(M++1,11.02),253(M+,62.47),238(M+-CH3,100);HRMS Calcdfor C16H15NO2(M+):253.1103,Found:253.1095.
实施例15
按实施例1所述的方法,不同的是所用底物和试剂为:二氯化铂(4.1mg,0.015mmol),N,N-二甲基-2-((1-乙基-吲哚-2-基)-羟甲基)-2,3-丁二烯酰胺(92.1mg,0.30mmol)和甲苯(1.5mL),然后在室温下24小时反应完全,浓缩,快速柱层析,得产物N,N-二甲基-(9-乙基-咔唑-2-基)酰胺71.6mg,产率为83%。产物为无色液体。
1HNMR(300MHz,CDCl3)δ8.16-8.04(m,2H),7.60-7.39(m,3H),7.30-7.20(m,2H),4.38(q,J=7.2Hz,2H),3.17(s,3H),3.06(s,3H),1.43(t,J=7.2Hz,3H);13CNMR(75MHz,CDCl3)δ172.5,140.5,139.4,133.3,126.2,123.8,122.3,120.7,120.0,119.1,117.6,108.6,107.8,39.9,37.6,35.5,13.8;IR(neat)v(cm-1)2973,2931,1631,1566,1483,1477,1444,1391,1327,1260,1234,1196,1157,1077;MS(70ev,EI)m/z(%)267(M++1,10.46),266(M+,55.07),222(M+-C2H6N,100);HRMS Calcd for C17H18N2O(M+):266.1419,Found:266.1418.
实施例16
按实施例1所述的方法,不同的是所用底物和试剂为:二氯化铂(5.3mg,0.02mmol),1-(1-乙基-吲哚-2-基)-2-羟甲基-2,3-丁二烯-1-醇(96.2mg,0.40mmol)和甲苯(2mL),然后在室温下23小时反应完全,浓缩,快速柱层析,得产物(9-苯基-咔唑-2-基)甲醇57.4mg,产率为64%。产物为无色液体。
1H NMR(300MHz,CDCl3)δ8.05(d,J=7.8Hz,1H),8.00(d,J=7.8Hz,1H),7.50-7.38(m,1H),7.37-7.30(m,2H),7.26-7.16(m,1H),7.13(d,J=8.1Hz,1H),4.81(s,2H),4.25(q,J=7.2Hz,2H),2.26(bs,1H),1.35(t,J=7.2Hz,3H);13C NMR(75MHz,CDCl3)δ140.1,140.0,138.6,125.5,122.6,122.3,120.33,120.29,118.7,117.8,108.4,106.8,65.9,37.3,13.7;IR(neat)v(cm-1)3345,3053,2975,2932,2872,1629,1601,1572,1498,1479,1470,1443,1379,1327,1236,1178,1156,1133,1086,1001;MS(70ev,EI)m/z(%)226(M++1,11.89),225(M+,72.38),210(M+-CH3,100);HRMS Calcd for C15H15NO(M+):225.1154,Found:225.1156.
实施例17
按实施例1所述的方法,不同的是所用底物和试剂为:二氯化铂(5.4mg,0.02mmol),1-(1-乙基-2-甲基-吲哚-2-基)-2-羟甲基-2,3-丁二烯-1-醇(102.5mg,0.40mmol)和甲苯(2mL),然后在室温下20小时反应完全,浓缩,快速柱层析,得产物(5-甲基-9-乙基-咔唑-2-基)甲醇77.4mg,产率为81%。产物为无色液体。
1HNMR(300MHz,CDCl3)δ8.18(d,J=7.8Hz,1H),7.52-7.40(m,2H),7.30(d,J=8.1Hz,1H),7.23(dJ=8.1Hz,1H),7.18-7.05(m,1H),4.90(s,2H),4.32(q,J=7.2Hz,2H),2.94(s,4H),1.43(t,J=7.2Hz,3H);13C NMR(75MHz,CDCl3)δ140.0,139.9,137.9,133.2,125.2,122.8,122.4,121.1,120.3,117.7,106.4,105.9,65.6,37.2,20.7,13.6;IR(neat)v(cm-1)3334,3049,2974,2933,2872,1624,1597,1489,1469,1447,1379,1322,1274,1253,1222,1187,1165,1152,1138,1105,1080,1012;MS(70ev,EI)m/z(%)240(M++1,12.90),239(M+,73.21),224(M+-CH3,100);HRMS Calcd for C16H17NO(M+):239.1310,Found:239.1315.
实施例18
按实施例1所述的方法,不同的是所用底物和试剂为:二氯化铂(5.5mg,0.02mmol),1-(1-乙基-7-甲基-吲哚-2-基)-2-羟甲基-2,3-丁二烯-1-醇(102.0mg,0.40mmol)和甲苯(2mL),然后在室温下21小时反应完全,浓缩,快速柱层析,得产物(8-甲基-9-乙基-咔唑-2-基)甲醇64.8mg,产率为68%。产物为无色液体。
1HNMR(300MHz,CDCl3)δ8.04(d,J=7.8Hz,1H),7.97(d,J=7.5Hz,1H),7.40(s,2H),7.25-7.10(m,3H),4.87(s,1H),4.52(q,J=7.0Hz,2H),2.82(s,3H),2.26(bs,1H),1.41(t,J=7.0Hz,3H);13C NMR(75MHz,CDCl3)δ140.7,138.8,138.5,128.8,123.4,122.6,120.01,119.95,118.9,118.1,118.0,107.0,66.0,39.2,20.0,15.6;IR(neat)v(cm-1)3346,3049,2975,2934,2873,1623,1597,1489,1469,1447,1379,1322,1274,1252,1222,1187,1165,1152,1138,1105,1080,1012;MS(70ev,EI)m/z(%)240(M++1,12.25),239(M+,67.62),224(M--CH3,100);HRMS Calcd for C16H17NO(M+):239.1310,Found:239.1311.
实施例19
按实施例1所述的方法,所用底物和试剂为:二氯化铂(5.3mg,0.02mmol),1-(1-乙基-吲哚-2-基)-2,3-丁二烯-1-醇(85.7mg,0.40mmol)和甲苯(2mL),然后在室温下4小时反应完全,浓缩,快速柱层析,得产物9-乙基-咔唑55.1mg,产率为70%。产物为无色液体。
1HNMR(300MHz,CDCl3)δ8.10(d,J=7.8Hz,2H),7.52-7.36(m,4H),7.23(td,J=7.2and 1.0Hz,2H),4.36(q,J=7.2Hz,2H),1.42(t,J=7.2Hz,3H);13C NMR(75MHz,CDCl3)δ139.9,125.6,122.9,120.4,118.7,108.4,37.4,13.8;IR(neat),v(cm-1)3423,3051,2975,2925,2877,1627,1598,1484,1469,1454,1381,1345,1327,1231,1153,1130,1120,1086,1053;MS (70ev,EI)m/z (%)196(M++1,9.34),195(M+,57.45),180(M+-CH3,100);HRMS Calcd for C14H13N(M+):195.1048,Found:195.1044.

Claims (5)

1、一种合成咔唑类化合物的方法,其特征是在二氯化铂的催化下,1-(吲哚-2-基)-2,3-联烯醇高区域选择性地发生反应合成官能团化咔唑,反应式如下:
Figure A2009100994820002C1
R1=H、烷基或苯基,其中烷基为CnH2n+1,式中n=1-2;R2=H或甲基;R3=H、烷基、烯丙基、苯基、酯基COOEt、酰胺基CON(CH3)2或醇羟基CH2OH,其中烷基为CnH2n+1,式中n=1-4;R4=H、烷基或苄基,其中烷基为CnH2n+1,式中n=1-6;R5=H或甲基,R6=H、甲基或甲氧基,R7=H或甲基,其步骤是:
(1)依次将1-(吲哚-2-基)-2,3-联烯醇、二氯化铂加入到甲苯中,然后在室温下搅拌反应2-19小时;
(2)浓缩,快速柱层析,得咔唑类化合物。
2、根据权利要求1所述的合成咔唑类化合物的方法,其特征是1-(吲哚-2-基)-2,3-联烯醇与二氯化铂的摩尔比为:1∶0.05-0.055。
3、根据权利要求2所述的合成咔唑类化合物的方法,其特征是1-(吲哚-2-基)-2,3-联烯醇与二氯化铂的摩尔比为:1∶0.05。
4、根据权利要求1所述的合成咔唑类化合物的方法,其特征是1-(吲哚-2-基)-2,3-联烯醇与甲苯的摩尔比为:0.18-0.2mmol/1mL。
5、根据权利要求4所述的合成咔唑类化合物的方法,其特征是1-(吲哚-2-基)-2,3-联烯醇与甲苯的摩尔比为:0.2mmol/1mL。
CN200910099482XA 2009-06-09 2009-06-09 一种合成咔唑类化合物的方法 Expired - Fee Related CN101585803B (zh)

Priority Applications (1)

Application Number Priority Date Filing Date Title
CN200910099482XA CN101585803B (zh) 2009-06-09 2009-06-09 一种合成咔唑类化合物的方法

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
CN200910099482XA CN101585803B (zh) 2009-06-09 2009-06-09 一种合成咔唑类化合物的方法

Publications (2)

Publication Number Publication Date
CN101585803A true CN101585803A (zh) 2009-11-25
CN101585803B CN101585803B (zh) 2012-07-04

Family

ID=41370255

Family Applications (1)

Application Number Title Priority Date Filing Date
CN200910099482XA Expired - Fee Related CN101585803B (zh) 2009-06-09 2009-06-09 一种合成咔唑类化合物的方法

Country Status (1)

Country Link
CN (1) CN101585803B (zh)

Cited By (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN102424666A (zh) * 2011-09-22 2012-04-25 浙江大学 一种合成天然咔唑类生物碱的制备方法
CN102633710A (zh) * 2012-03-29 2012-08-15 南通海迪化工有限公司 一种合成咔唑类化合物的方法
CN103044313A (zh) * 2012-12-06 2013-04-17 浙江大学 一种合成咔唑类化合物的方法
CN104030970A (zh) * 2014-06-26 2014-09-10 浙江大学 一种合成咔唑类化合物的新方法
CN106631969A (zh) * 2016-12-14 2017-05-10 江汉大学 咔唑及其衍生物的合成方法
CN114539054A (zh) * 2022-01-29 2022-05-27 武汉大学 一种模块化合成多取代三氟甲基联烯的方法

Cited By (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN102424666A (zh) * 2011-09-22 2012-04-25 浙江大学 一种合成天然咔唑类生物碱的制备方法
CN102424666B (zh) * 2011-09-22 2014-04-30 浙江大学 一种合成天然咔唑类生物碱的制备方法
CN102633710A (zh) * 2012-03-29 2012-08-15 南通海迪化工有限公司 一种合成咔唑类化合物的方法
CN103044313A (zh) * 2012-12-06 2013-04-17 浙江大学 一种合成咔唑类化合物的方法
CN103044313B (zh) * 2012-12-06 2014-10-22 浙江大学 一种合成咔唑类化合物的方法
CN104030970A (zh) * 2014-06-26 2014-09-10 浙江大学 一种合成咔唑类化合物的新方法
CN104030970B (zh) * 2014-06-26 2016-04-20 浙江大学 一种合成咔唑类化合物的新方法
CN106631969A (zh) * 2016-12-14 2017-05-10 江汉大学 咔唑及其衍生物的合成方法
CN114539054A (zh) * 2022-01-29 2022-05-27 武汉大学 一种模块化合成多取代三氟甲基联烯的方法
CN114539054B (zh) * 2022-01-29 2023-02-17 武汉大学 一种模块化合成多取代三氟甲基联烯的方法

Also Published As

Publication number Publication date
CN101585803B (zh) 2012-07-04

Similar Documents

Publication Publication Date Title
CN101585803B (zh) 一种合成咔唑类化合物的方法
CN109400580B (zh) 3,4-二氨基吡啶氮氧类手性催化剂及其在Steglich重排中的应用
Lee et al. Pd‐Catalyzed ortho‐Selective Oxidative Coupling of Halogenated Acetanilides with Acrylates
JP5222632B2 (ja) ビアリール化合物の製造方法
CN108264469A (zh) 一种制备2-(亚环己烯基)丙二酸衍生物的方法及其应用
Hamper et al. Knoevenagel condensation of unsymmetrical malonamic esters and malonates on a solid support
Oswald et al. Negishi cross-coupling reactions of α-amino acid-derived organozinc reagents and aromatic bromides
CN107141258B (zh) 一种由环酮腙合成侧链官能团化4-酰基吡唑类化合物的方法
Kumar et al. Phosphomolybdic acid-Al2O3: A mild, efficient, heterogeneous and reusable catalyst for regioselective opening of oxiranes with amines to β-amino alcohols
CN109503547B (zh) 苯并二硫环戊二烯衍生物的制备方法
CN113754544B (zh) 一种多取代(e)-三氟甲基烯烃的制备方法
CN108689874B (zh) 一种制备2-芳基丙二酰胺的方法及其应用
CN111187176B (zh) 一种铜盐催化的制备n-乙烯基酰胺类化合物的方法
CN107216326A (zh) (1,2,3‑三氮唑)[1,5‑f]菲啶‑10‑羧酸乙酯类化合物的合成方法
CN109320538B (zh) 3-溴-5-芳基-2-(三甲基硅基)-1-(n,n-二甲基磺酰胺)吡咯合成方法
Krishnan et al. Aminated poly (vinyl chloride): An efficient green catalyst for Knoevenagel condensation reactions
CN109180520B (zh) 一种银催化合成官能化苯并芴类化合物的方法
CN108264449B (zh) 一种2,6-二乙基-4-甲基苯酚的制备方法
Fisher et al. Palladium-catalysed nucleophilic release of allylic amines from a phenolic resin
CN111995636B (zh) 一种邻羟基-氮硅烷化合物及其合成方法
JP6588924B2 (ja) ルテニウムの触媒作用によってアニリド類からビフェニルアミン類を製造する方法
CN104030923B (zh) 一种混旋丹参素冰片酯的合成方法
CN108383754A (zh) 一类芳基肟脂化合物的制备方法和应用
TW201713626A (zh) 芳香族化合物之製造方法
CN109694332A (zh) 一种苄胺衍生物烯基化的方法

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
C14 Grant of patent or utility model
GR01 Patent grant
CF01 Termination of patent right due to non-payment of annual fee

Granted publication date: 20120704

Termination date: 20150609

EXPY Termination of patent right or utility model